Inhibition of the PINK1-Parkin Pathway Enhances the Lethality of Sorafenib and Regorafenib in Hepatocellular Carcinoma

• Main Authors: Shun Zhang (Author), Yixin Wang (Author), Yifan Cao (Author), Jin Wu (Author), Zubin Zhang (Author), Haigang Ren (Author), Xiaohui Xu (Author), Elena Kaznacheyeva (Author), Qing Li (Author), Guanghui Wang (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Hepatocellular carcinoma (HCC) is one of the most common fatal malignancies and the main cause of cancer-related deaths. The multitarget tyrosine kinase inhibitors (TKIs) sorafenib and regorafenib are systemic therapeutic drugs approved for the treatment of HCC. Here, we found that sorafenib and reg...